Xi'an Janssen biologics, the drug, is released subcutaneously every three months.

Posted on

Medical Network June 10, Johnson & Johnson's pharmaceutical subsidiary Xi'an Yangsen Pharmaceutical Co., Ltd. announced that the world's first all-human "double-targeted" interleukin 12 (IL-12) and interleukin 23 (IL-23) The inhibitor STELARA®, the Ussuzumab injection, is available in China. Hedano® is an innovative delivery mode – a biologic that is administered subcutaneously every three months during maintenance to treat cyclosporine, methotrexate (MTX) or PUVA (psoralen and Ultraviolet A) and other systems for the treatment of patients with moderate to severe plaque psoriasis who are unresponsive, contraindicated or intolerant.
Starrino® is a fully humanized monoclonal antibody directed against IL-12 and IL-23, which is specifically inhibited by high affinity binding to the p40 protein subunit shared by IL-12 and IL-23. Two cytokines that play a key role in the development and progression of psoriasis.
Two randomized, double-blind, placebo-controlled phase III clinical trials involving PHOENIX 1 and PHOENIX 2 in 1996 patients showed that the long-term efficacy of the Cedano® was long-lasting, maintaining skin lesion clearance and improving quality of life for up to five years. Another phase III clinical trial of LOTUS for the Chinese population showed that 82.5% (132/60) of patients who received idino® achieved a primary endpoint of PASI75 at 12 weeks, compared with 11.1% of the placebo group. Significant improvements were also made to all key secondary endpoints, including more than 80% of patients who received the Gyano® achieved PASI90 at 28 weeks.
In addition, the PHOENIX Extended Extension Study 4 [6] showed that idino® maintained a long-term clinical response to psoriasis, and no dose-related or cumulative toxicity was observed with the duration of treatment with idino®. The real-world PSOLAR study included more than 12,000 patient data using idino® and other treatments over the course of 8 years, and the results were consistent with the overall safety of the idino®. In addition, multiple real-world registry studies have shown that the total drug retention rate of the Gyano® is higher and the risk of discontinuation is lower compared to other biologics included in the study.
At present, the company has entered China, covering cities such as Beijing, Shanghai and Guangzhou.

Ultrasound Therapy Device

Instrument
Imaging mode: 1-2-3D, real time display
Locating system: Three dimensional motor platform
Scanning mode: 2Dgalvanometric scanning system
Lateral resolution: 3.8 um
Axial resolution: 4I um
Image depth: 0-2 mm
Speed: 1-50 frame/s

Clinical PW A detection
Port wine stains ( PWS ) is always a birthmark . It is caused by a vascular anomaly. PA imaging could provide real-time information about the thickness of the skin and diameter. depth, distribution of blood vessel , which provide significant help with clinical diagnosis and treatment.

PAI VS. OCT
Image depth : PA 2 mm
OCT 0.4 mm
Functional identification : With optical fingerprint characteristics ,P A could specificity imaging blood vessels , eliminates the interference of hair follicle, sebaceous glands.


The clinical testing has been carried out in 301 and guangzhou military general hospital , testing and statistic all kinds of PWS lesions in patients with vasculal parameters , in order to establish the classification and quantitative treatment of PWS.

Ultrasound Therapy Device,Ecg Machine,Ecg Machine 12 Channel,Electrocardiograph Machine 6 Channel,Three Channel Ecg Machine

Guangzhou Sonostar Technologies Co., Limited , https://www.sonoeye.com